針對局部晚期攝護腺癌使用機器手臂根除性攝護腺併骨盆腔淋巴廓清手術治療:
單一團隊經驗
張英傑、吳錫金、張兆祥、楊啟瑞、黃志平*
中國醫藥大學附設醫院 泌尿部
Robotic radical prostatectomy for pathologic locally advanced prostate cancer, including pT3a, pT3b, pT4, and any TN1: single team experience
Ying-Chieh Chang, Hsi-Chin Wu, Chao-Hsiang Chang, Chi-Rei Yang, Chi-Ping Huang*
Department of Urology, China Medical University Hospital, Taichung, Taiwan
Purpose:
Prostate cancer has become the highest incident cancer among men worldwide. Robotic assisted laparoscopic radical prostatectomy is a widely used method to treat prostate cancer. Surgeons who perform radical prostatectomy (RP) continuously accumulate experience and develop their technical skills, resulting in improved urinary continence and sexual health and decrease margin positive rate. We share our outcome of RALRP for locally advanced (pT3a, pT3b, pT4 and any TN1)prostate cancer.
Materials and Methods:
Between January 2014 and December 2018, 119 patients underwent robotic radical prostatectomy in our institution. Inclusion criteria was pathological T3a, T3b, T4 and TN1, so 35 cases were enrolled. We analyzed age, cancer risk, iPSA and perioperative outcomes including biochemical failure rate, margin positive rate, time to continency time and potency using Kaplan-Meiter method.
Results:
From 2014 to 2018, 35 patientes with locally advanced PCa underwent RARP and BPLND. The clinical outcomes were as below: Margin positive rate:65.7% , Biochemical failure rate: 17.1% ,5- year continency rate:83%.
Conclusion:
Our panta-factor outcomes are acceptable for patients with locally advanced prostate cancer underwent robotic radical prostatectomy.